Skip to main content

CORRECTION article

Front. Immunol., 07 June 2021
Sec. Cancer Immunity and Immunotherapy
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.713268
This article is part of the Research Topic Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer, Colon Cancer and Esophageal Cancer View all 48 articles

Corrigendum: Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

This article is a correction to:

  1. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

    1. Read original article
Yuzhong Chen&#x;Yuzhong Chen1†Shaodi Wen&#x;Shaodi Wen1†Jingwei XiaJingwei Xia1Xiaoyue DuXiaoyue Du1Yuan WuYuan Wu1Banzhou PanBanzhou Pan1Wei ZhuWei Zhu2Bo Shen*Bo Shen1*
  • 1The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
  • 2Key Hematological of Medical Science and Hematological Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, China

A Corrigendum on
Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

By Chen Y, Wen S, Xia J, Du X, Wu Y, Pan B, Zhu W and Shen B (2021). Front. Immunol. 12:672271. doi: 10.3389/fimmu.2021.672271

In the original article, there was an error in the Ethics Statement: “The studies involving human participants were reviewed and approved by the Ethics Committee of the First Hospital of Shanxi Medical University. The patients/participants provided their written informed consent to participate in this study.”

A correction has been made:

“The study involving human participants was reviewed and approved by the Ethics Committee of Jiangsu Cancer Hospital. Patient’s informed consent was not necessary because this study was a retrospective study.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: non-small cell lung cancer, PD-1 inhibitor, combination therapy, carcinoembryonic antigen, neutrophil-to-lymphocyte ratio, neuron-specific enolase

Citation: Chen Y, Wen S, Xia J, Du X, Wu Y, Pan B, Zhu W and Shen B (2021) Corrigendum: Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer. Front. Immunol. 12:713268. doi: 10.3389/fimmu.2021.713268

Received: 22 May 2021; Accepted: 24 May 2021;
Published: 07 June 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Chen, Wen, Xia, Du, Wu, Pan, Zhu and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Bo Shen, shenbo987@126.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.